Drug intelligence / Profile preview

BP27

Development stage: Preclinical
Lead developer: CuraTeQ Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BP27 is a biosimilar monoclonal antibody candidate being developed by CuraTeQ Biologics, a subsidiary of Aurobindo Pharma. The drug is currently in the pipeline for oncology indications, though the specific reference product and molecular target remain undisclosed. As a biosimilar, BP27 is intended to demonstrate no clinically meaningful differences in safety and efficacy compared to its reference biologic, aiming to expand patient access to targeted cancer therapies.

Beyond the preview

Go deeper on BP27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP27.

Explore the full profile